Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GlaxoSmithKline completes sale of remaining Aspen shares
GSK has agreed to the sale of 28.2 million ordinary shares in Aspen Pharmacare Holdings Ltd ("Aspen") at a price of ZAR 300 per share.
-
GlaxoSmithKline announces intention to sell remaining holding in Aspen
GSK intends to sell its remaining stake in Aspen Pharmacare Holdings Ltd ("Aspen").
-
GSK announces US regulatory submission for sirukumab in rheumatoid arthritis
Sirukumab is being co-developed for RA as part of a collaboration with Janssen Biologics (Ireland) [Janssen], an affiliate of JBI.
-
GSK announces regulatory submissions for subcutaneous formulation of Benlysta® (belimumab) for patients with systemic lupus disease
It has filed regulatory submissions in the US and Europe for Benlysta® (belimumab) for approval.
-
Emma Walmsley to succeed Andrew Witty as Chief Executive Officer of GlaxoSmithKline
Emma Walmsley, currently CEO of GSK’s Consumer Healthcare division, is appointed GSK CEO Designate and will succeed Andrew Witty as GSK CEO.
-
GSK sets out further steps to address emerging global health security challenges
GSK will set out a series of steps to further address emerging global health challenges
-
GSK’s candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM
GSK on track to file regulatory applications in 2016
-
GSK announces EU regulatory submission for sirukumab in rheumatoid arthritis
Sirukumab is being co-developed for RA as part of a collaboration with Janssen Biologics (Ireland) [Janssen].
-
GSK divests non-core assets to Aspen
A series of agreements Between Aspen and GSK through focusing on core therapeutic areas
-
GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD at ERS International Congress
Improvements in lung function and health-related quality of life supported by statistically significant reductions in exacerbations
-
‘Real world’ data shows 83 percent effectiveness for Bexsero® in infants in first year of UK national meningitis B immunisation programme
Cases of meningitis B halved after ten months
-
GSK announce positive results from the COPD Salford Lung Study published in the NEJM and presented at European Respiratory Congress
The results from the pioneering Salford Lung Study (SLS) have been published in the New England Journal of Medicine (NEJM).
-
NEJM publishes results of GSK’s long-term LABA safety study of Advair® Diskus® in children aged 4-11 years with asthma
Headline results reported in March, demonstrated that the study had achieved its primary endpoint.
-
GSK’s continued commitment to innovative respiratory research demonstrated in European Respiratory Society congress data presentations
More than 30 abstracts from the company will be featured at the meeting.
-
ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment
HIV care is a long-term prospect for those living with the disease, requiring life-long adherence to treatment.
-
GSK and Verily to establish Galvani Bioelectronics – a new company dedicated to the development of bioelectronic medicines
GSK will hold a 55% equity interest in the new jointly owned company and Verily will hold 45%.
-
GSK in-licenses anti-IL-33R monoclonal antibody for severe asthma from Janssen
Agreement further strengthens respiratory pipeline of targeted biological therapies
-
Results announcement for the second quarter 2016 and half-yearly financial report for the half-year 2016
GSK delivers further progress against strategy with strong Q2 performance
-
GSK announces significant new investment in UK manufacturing network
GSK today announced £275 million of new investments at three of its manufacturing sites in the UK
-
ARIA study shows superior efficacy of Triumeq® for treatment-naïve women living with HIV
ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study
